TY - JOUR
T1 - Telomere content and risk of second malignant neoplasm in survivors of childhood cancer
T2 - A report from the childhood cancer survivor study
AU - Gramatges, Maria M.
AU - Liu, Qi
AU - Yasui, Yutaka
AU - Okcu, M. Fatih
AU - Neglia, Joseph P.
AU - Strong, Louise C.
AU - Armstrong, Gregory T.
AU - Robison, Leslie L.
AU - Bhatia, Smita
PY - 2014
Y1 - 2014
N2 - Purpose: Shorter constitutional telomere length has been associated with increased cancer incidence. Furthermore, telomere shortening is observed in response to intensive chemotherapy and/or ionizing radiation exposure. We aimed to determine whether less telomere content was associated with treatmentrelated second malignant neoplasms (SMN) in childhood cancer survivors. Experimental Design: Using a nested case-control design, 147 cancer survivors with breast cancer, thyroid cancer, or sarcoma developing after treatment for childhood cancer (cases) were matched (1:1) with childhood cancer survivors without a SMN (controls). Cases and controls were matched by primary cancer diagnosis, years since diagnosis, age at the time of sample collection, years of follow-up from childhood cancer diagnosis, exposure to specific chemotherapy agents, and to specific radiation fields. We performed conditional logistic regression using telomere content as a continuous variable to estimate ORs with corresponding 95% confidence intervals (CI) for development of SMN. ORs were also estimated for specific SMN types, i.e., breast cancer, thyroid cancer, and sarcoma. Results: There was an inverse relationship between telomere content and SMN, with an adjusted OR of 0.3 per unit change in telomere length to single-copy gene ratio (95% CI, 0.09-1.02; P=0.05). Patients with thyroid cancerSMNwere less likely to have more telomere content (OR, 0.04; 95% CI, 0.00-0.55; P=0.01), but statistically significant associations could not be demonstrated for breast cancer or sarcoma. Conclusions: A relation between less telomere content and treatment-related thyroid cancer was observed, suggesting that shorter telomeres may contribute to certain SMNs in childhood cancer survivors.
AB - Purpose: Shorter constitutional telomere length has been associated with increased cancer incidence. Furthermore, telomere shortening is observed in response to intensive chemotherapy and/or ionizing radiation exposure. We aimed to determine whether less telomere content was associated with treatmentrelated second malignant neoplasms (SMN) in childhood cancer survivors. Experimental Design: Using a nested case-control design, 147 cancer survivors with breast cancer, thyroid cancer, or sarcoma developing after treatment for childhood cancer (cases) were matched (1:1) with childhood cancer survivors without a SMN (controls). Cases and controls were matched by primary cancer diagnosis, years since diagnosis, age at the time of sample collection, years of follow-up from childhood cancer diagnosis, exposure to specific chemotherapy agents, and to specific radiation fields. We performed conditional logistic regression using telomere content as a continuous variable to estimate ORs with corresponding 95% confidence intervals (CI) for development of SMN. ORs were also estimated for specific SMN types, i.e., breast cancer, thyroid cancer, and sarcoma. Results: There was an inverse relationship between telomere content and SMN, with an adjusted OR of 0.3 per unit change in telomere length to single-copy gene ratio (95% CI, 0.09-1.02; P=0.05). Patients with thyroid cancerSMNwere less likely to have more telomere content (OR, 0.04; 95% CI, 0.00-0.55; P=0.01), but statistically significant associations could not be demonstrated for breast cancer or sarcoma. Conclusions: A relation between less telomere content and treatment-related thyroid cancer was observed, suggesting that shorter telomeres may contribute to certain SMNs in childhood cancer survivors.
UR - http://www.scopus.com/inward/record.url?scp=84896735329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896735329&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-2076
DO - 10.1158/1078-0432.CCR-13-2076
M3 - Article
C2 - 24277454
AN - SCOPUS:84896735329
SN - 1078-0432
VL - 20
SP - 904
EP - 911
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -